BSE · 524444
Evexia Lifecare Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹25 Cr with net profit ₹0 Cr — a 1.87% net margin, versus 1.67% the period before.
Shareholding
As of 2026-03-31
- Promoter3.36%
- Public96.41%
- FII0.12%
- DII0.1%
1,44,416 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 5.15× from low to high.
Risk flags
Derived from disclosed data
- Under exchange surveillance — ESM · ESM 1. Trading may carry price bands, periodic call auction or higher margins.
- 52-week range spans 5.15× (₹0.47 to ₹2.42) — an unusually wide band.
Peer comparison
Trading · ranked #113 of 666 by market cap · medians across 50 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Adani Enterprises Limited | ₹3,89,556 Cr | 24.35 | 4.78 | 3.42% | 9.3% |
| Avenue Supermarts Limited | ₹2,51,168 Cr | 381.69 | 10.26 | 12.14% | 4.32% |
| Trent Ltd. | ₹1,58,818 Cr | 92.01 | 22.74 | 24.62% | 8.57% |
| FSN E-Commerce Ventures Ltd. | ₹94,034 Cr | 1216.11 | 65.38 | 13.87% | 1.99% |
| Vishal Mega Mart Limited | ₹50,942 Cr | 57.24 | 6.86 | 11.32% | 6.61% |
| Premier Energies Limited | ₹46,784 Cr | 101.64 | 10.84 | 35.05% | 19.3% |
| Aegis Logistics Limited | ₹45,167 Cr | 110.08 | 7.46 | 14.83% | 10.78% |
| Aditya Infotech Limited | ₹40,150 Cr | 237.08 | 21.38 | 19.61% | 8.72% |
| Redington Limited | ₹21,999 Cr | 56.17 | 2.17 | 14.67% | 1.25% |
| Honasa Consumer Limited | ₹14,736 Cr | 212.63 | 10.44 | 14.16% | 8.36% |
| Evexia Lifecare Limited(this company) | ₹291 Cr | 155 | 0.54 | 0.25% | 1.88% |
AI analysis
AI-generated · google/gemini-2.5-flashEvexia Lifecare Limited is listed with a market capitalization of Rs 310 Cr. The company reported a revenue of Rs 57.15 Cr and a profit margin of 188.4%.
Positives
- +The Return on Equity (ROE) is 25.3%, indicating a positive return on shareholder funds.
- +The company reported a high profit margin of 188.4%.
Negatives
- −The debt-to-equity ratio is high at 6.76, suggesting a substantial amount of debt relative to equity.
- −Promoter holding is low at 3.3642% as of March 31, 2026.
- −The company is under ESM surveillance, specifically ESM Stage 1.
- −The quarterly net profit has been inconsistent, showing a loss of Rs 0.49 Cr in Mar 2025.
- −The Price to Earnings (PE) ratio is high at 165.
Financial Performance
The company's revenue for the last five annual periods shows growth from Rs 15.18 Cr in Mar 2025 to Rs 25.18 Cr in Mar 2026. Net profit has fluctuated, showing a loss of Rs 0.49 Cr in Mar 2025 before rising to Rs 0.47 Cr in Mar 2026. Quarterly revenue also shows variation, from Rs 21.7 Cr in Dec 2024 to Rs 36.79 Cr in Mar 2026.
Profitability & Returns
Evexia Lifecare Limited has an EPS of 0.01 and a ROE of 25.3%. The reported profit margin is 188.4%. The ROCE stands at 0.1334. The company's PE ratio is 165.
Balance Sheet
The company has a book value of Rs 2.87. The debt-to-equity ratio is 6.76, indicating a significant reliance on debt for financing. Further details on assets and liabilities are not provided in the available data.
Ownership & Pledges
As of March 31, 2026, promoter holding in Evexia Lifecare Limited stood at 3.3642%, with public shareholding at 96.4139%. No promoter shares have been reported as pledged.
Regulatory & Surveillance
Evexia Lifecare Limited is under the ESM framework, specifically ESM Stage 1, indicating enhanced surveillance measures are in place due to certain criteria being met.
Data as of — price: 2026-07-29 · financials: Mar 26 · shareholding: Mar 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.